Swiss National Bank Voyager Therapeutics, Inc. Transaction History

Swiss National Bank

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 06, 2021	SELL	$3.94 - $5.44 $211,972 - $292,672	-53,800 Closed	0 $0
Q2 2020 Aug 05, 2020	BUY	$8.05 - $14.21 $6,440 - $11,368	800 Added 1.51%	53,800 $679,000
Q4 2019 Feb 06, 2020	BUY	$12.82 - $16.85 $15,384 - $20,220	1,200 Added 2.32%	53,000 $739,000
Q3 2019 Nov 12, 2019	BUY	$16.31 - $28.29 $102,752 - $178,227	6,300 Added 13.85%	51,800 $891,000
Q2 2019 Aug 02, 2019	BUY	$19.18 - $27.88 $195,636 - $284,376	10,200 Added 28.9%	45,500 $1.24 Million
Q2 2018 Aug 09, 2018	BUY	$16.76 - $23.92 $98,884 - $141,128	5,900 Added 20.07%	35,300 $690,000
Q4 2017 Feb 07, 2018	BUY	$12.26 - $25.88 $360,444 - $760,872	29,400	29,400 $488,000

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $207M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.